Is blocking antibody therapy successful?

Because blocking antibodies can easily lead to miscarriage during pregnancy, the impact on women is relatively large. Aspirin therapy can be used for treatment. More importantly, it is recommended that women should wait until the treatment is complete before getting pregnant.

1. Spouse leukocyte immunotherapy

The procedure involves first separating and extracting lymphocytes from the husband and injecting them subcutaneously into the wife's body to build a safety barrier for the fetus in the mother's womb. If for various reasons immunotherapy between husband and wife is unsuccessful, lymphocytes from a third party (who has passed a health check) can be used instead. This will not change any genetic characteristics of the fetus. This treatment has been carried out for a long time, has a definite effect, and the successful pregnancy rate can reach over 90%. However, it takes a long time, brings great inconvenience to some non-local patients, and costs a lot. In addition, if the man has certain blood-borne infectious diseases (such as hepatitis B, HIV positive, etc.), this method is not suitable.

2. Oral cyclosporine a treatment

For patients who are not suitable for spouse's leukocyte immunotherapy, we use oral cyclosporine a to maintain pregnancy. The plan is: continuous monitoring of basal body temperature. After the basal body temperature rose for one week, cyclosporine A was taken orally for 20 consecutive days. Cyclosporine A is a traditional immunosuppressant widely used in the treatment of organ transplantation and autoimmune diseases. Its application during pregnancy is mainly concentrated in pregnant women after organ transplantation. Its application in women with habitual miscarriage is a new development in the treatment of cyclosporine a. Our study confirmed that cyclosporine a can effectively promote trophoblast function and induce maternal-fetal immune tolerance. According to clinical statistics, the effectiveness of cyclosporine a in treating habitual abortion is over 85%.

3. Does cyclosporine A have teratogenic effects on the fetus?

Although animal experiments have found that high doses of cyclosporine A during pregnancy may cause embryonic nephrotoxicity, in humans, the use of therapeutic doses of cyclosporine A during pregnancy has no teratogenic effect on the fetus except for increasing the incidence of intrauterine growth retardation and premature birth. No abnormalities were found in the follow-up of the newborn after birth. What's more, the dose for treating habitual abortion is much smaller than the dose used after organ transplantation, and the treatment course is also short, so it can be used safely during pregnancy.